TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...
In our experience, these 2 cases were the 69 th and 93 rd cases. At the early stage in the learning curve of robotic surgery, RALP would have been difficult to perform in both of these cases, ...
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...
— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...
Original Medicare (parts A and B) covers medically necessary prostate surgeries, including treatments for an enlarged prostate and prostate cancer. Medicare covers various prostate procedures, ...
We recently reported our initial experience with single-port transvesical enucleation of the prostate (STEP) performed through a solitary suprapubic incision via a single-access port inserted directly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results